Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.
- Multi-market revenue generation across Europe, MENA, Japan, and Australia
- Recurring revenue model driven by single-use cartridge sales
- Improved unit economics with target pricing and cost of goods sold
- Regulatory approvals enabling rapid market expansion
- Near-term catalysts include India regulatory completion and reseller expansion
Investor Webinar and Updated Presentation
Memphasys Limited (ASX:MEM) has scheduled an investor webinar for 8 April 2026, where Director Marjan Mikel will present an updated investor presentation. The presentation outlines the company’s progress as it moves from early-stage commercialisation of its patented Felix™ System towards scaling global revenues. This webinar forms part of a broader investor engagement program aimed at providing detailed insights into Memphasys’ commercial strategy and financial profile.
Commercial Progress and Multi-Market Revenue
The updated presentation reveals that Memphasys is now generating revenue across multiple jurisdictions, including Europe, the Middle East and North Africa (MENA), Japan, and Australia. The company reported a significant step-change in revenue during the March 2026 quarter, driven by contributions from Italy and Qatar. Early sales figures indicate a transition from validation to commercial scale, with repeat cartridge orders validating the consumables-based usage model that underpins recurring revenue.
Key commercial agreements include a multi-year supply deal with CFA Italia in Italy, an exclusive five-year agreement with ITL in the MENA region, and ongoing repeat orders from Qatar’s Hamad Medical Corporation. In Japan, commercial orders have been ongoing since 2023, with repeat cartridge sales confirming adoption in routine clinical practice. The company is also advancing regulatory submissions and commercial discussions in India and Australia/New Zealand (ANZ) markets.
Recurring Revenue Model and Unit Economics
Memphasys’ business model centres on a consumables-driven revenue stream, where each assisted reproductive technology (ART) procedure requires a single-use Felix™ cartridge. This model creates an annuity-style revenue stream that scales with IVF procedure volumes at clinics. The company targets cartridge pricing between AUD 80 and AUD 150, with a cost of goods sold (COGS) below AUD 40, aiming for gross margins exceeding 60%. This margin profile, combined with operating leverage from minimal incremental costs per procedure, suggests potential for margin expansion as volumes increase.
The presentation highlights that annual revenue per clinic could range from AUD 100,000 to AUD 300,000, driven by procedure volume growth rather than solely new customer acquisition. This recurring revenue model is supported by commercial supply agreements with defined minimum purchase commitments, providing some visibility into future revenue streams.
Regulatory Approvals and Market Expansion
Regulatory progress is a key enabler of Memphasys’ commercial rollout. The Felix™ System holds CE Mark approval for Europe, Therapeutic Goods Administration (TGA) approval in Australia, and registration with the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. These approvals facilitate market access across high-regulatory jurisdictions and support expansion into CE-recognised markets such as MENA and parts of Asia-Pacific.
India’s regulatory approval process (CDSCO) is underway, with expectations of completion within approximately six months. The company is also advancing commercialisation efforts in ANZ and expanding reseller partnerships to support recurring consumables sales. These regulatory and commercial developments are positioned as near-term catalysts for revenue growth.
Technology and Market Opportunity
The Felix™ System utilises patented electrophoresis technology to isolate the highest-quality sperm cells rapidly and gently, offering an alternative to traditional centrifugation methods that can cause cellular stress and DNA damage. The system reduces sperm preparation time from approximately 45 minutes to six minutes, standardises workflow, and is designed to improve clinical outcomes such as embryo utilisation and pregnancy rates.
The global fertility market is projected to grow from USD 36 billion in 2024 to USD 85 billion by 2034, driven in part by declining sperm quality and increasing demand for assisted reproductive technologies. Memphasys aims to establish Felix™ as a new global standard in sperm preparation, leveraging its clinical validation and regulatory approvals to capture market share.
Outlook and Upcoming Catalysts
Memphasys has mapped out significant news flow over the next six months, including scaling commercial operations in Europe, MENA, and Asia-Pacific, completing India’s regulatory approval, advancing cost of goods sold improvements, expanding reseller networks, and driving recurring revenue growth. The company emphasises that its commercial strategy, focused on direct clinic engagement and high-value markets, is delivering measurable revenue outcomes.
Recent coverage has noted Memphasys’ expansion in MENA despite regional challenges and its accelerated commercialisation following regulatory wins and cost reductions. These developments provide additional context to the company’s current update and strategic direction.
Bottom Line?
Memphasys is progressing its transition to a scalable, recurring revenue model supported by regulatory approvals and multi-market commercial agreements, though execution risks and regulatory timelines remain key factors to monitor.
Questions in the middle?
- How will the timing of India’s CDSCO approval impact Memphasys’ revenue growth trajectory?
- What are the company’s plans to manage cost of goods sold improvements and their effect on gross margins?
- How effectively can Memphasys expand its reseller network to sustain recurring consumables sales across diverse markets?